ASP 8731
Alternative Names: ASP-8731; ML-0207Latest Information Update: 09 May 2023
At a glance
- Originator Mitobridge
- Developer Astellas Pharma; Mitobridge
- Class Antianaemics; Small molecules
- Mechanism of Action BACH1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sickle cell anaemia
Most Recent Events
- 30 Apr 2023 Discontinued - Phase-I for Sickle cell anaemia (In volunteers, In adults) in USA (PO)
- 01 Mar 2023 Astellas Pharma terminates phase I trial in Sickle cell anaemia (In volunteers, In adults) in USA (PO) so as protocol defined stopping criteria meets (NCT05167526)
- 01 Sep 2022 ASP 8731 receives Orphan Drug status for Sickle cell anaemia in USA